Search

SoHO

Substances of Human Origin (SoHO)

EHA has been involved in the evaluation and revision of EU legislation on human blood and blood components, from the start of process in 2016 to the presentation of the European Commission’s proposed Substances of Human…

Read more

Myelodysplastic Syndromes (MDS)

The SWG on Myelodysplastic Syndromes (MDS) focuses on the promotion and exchange of scientific and clinical evidence, ideas and projects in the field of MDS.

Read more

GAPP Joint Action

Joint Actions are projects designed and financed by Member State Authorities and the EU to address specific priorities under the EU Health Program.

Read more

Myeloproliferative neoplasms better understood through scientific meeting

The EHA-SWG Scientific Meeting on Challenges in the Diagnosis and Management of Myeloproliferative Neoplasms held on October 12-14, 2017 in Budapest, Hungary received a 100% recommendation rating from attendees.

Read more

Policy & advocacy

At the core of EHA’s advocacy efforts are four priority themes. For each of these themes, the main messages and recommendations directed at EU institutions and other stakeholders have been written down in a Position Paper.

Read more

EU health policy: limited scope, high ambition

Over the past decades, the European Union (EU) has become more involved in public health policy. A recent study showed that a majority of policymakers even identifies EU health policy as a priority for 2020-20241.

Read more

Clinical trials

The advance of highly innovative, increasingly personalized therapies in hematology requires novel clinical trial designs and more flexible, adaptive regulatory frameworks and improved data generation to support decision making both during and after clinical studies.

Read more